HBK Investments’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

HBK Investments’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-6,486,100	Closed	-$19.5M	–	598
2019 Q4	$19.5M	Buy	+6,486,100	New	+$16.9M	0.19%	56

Other funds holding BMY.RT

JCI

Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return

TNB

Thomasville National Bank Thomasville, Georgia $1.82B AUM

WAM

Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return

IAIM

International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

HBK Investments's BMY.RT Position: Q1 2021 in Review

HBK Investments sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 7,000,100 shares — an estimated $3.5M sold.

HBK Investments first reported a position in BMY.RT in Q2 2020 and held it in 3 quarters. The position peaked at $21.5M in Q2 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

HBK Investments reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
HBK Investments sold 7,000,100 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $3.5M.
HBK Investments first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q2 2020 and held it in 3 quarters.
HBK Investments's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $21.5M in Q2 2020.
12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on HBK Investments's 13F filing for Q1 2021, filed 17 May 2021.